1. Home
  2. GSBD vs YDES Comparison

GSBD vs YDES Comparison

Compare GSBD & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSBD

Goldman Sachs BDC Inc.

N/A

Current Price

$9.06

Market Cap

1.0B

Sector

Finance

ML Signal

N/A

YDES

YD Bio Limited Ordinary Shares

N/A

Current Price

$7.56

Market Cap

894.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GSBD
YDES
Founded
2012
2013
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
894.2M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
GSBD
YDES
Price
$9.06
$7.56
Analyst Decision
Sell
Analyst Count
2
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
1.5M
11.3K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
14.46%
N/A
EPS Growth
87.27
N/A
EPS
1.03
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.81
$7.51
52 Week High
$12.43
$25.00

Technical Indicators

Market Signals
Indicator
GSBD
YDES
Relative Strength Index (RSI) 41.95 29.22
Support Level $8.94 N/A
Resistance Level $9.53 $13.19
Average True Range (ATR) 0.23 0.52
MACD -0.00 -0.00
Stochastic Oscillator 40.44 0.00

Price Performance

Historical Comparison
GSBD
YDES

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Share on Social Networks: